Table 2 Themes, sub-themes and codes
Themes | Sub-themes | Codes |
|---|---|---|
The value of NCMs | NCM clinical significance | NMC significance NCM advances NCM challenges NCM adverse effects NCMs for hope |
NCM costs and price | NCM prices—facts NCM prices—opinions Acceptable prices for QALY Drug budgets | |
NCMs and health care | Cancer care systematic issues Cancer care advances Health care resources NCM equity NCMs and cancer care dilemmas | |
Introduction of NCMs | EMA market approval of NCMs | EMA market approval, EMA conditional market approval |
National introductory system (as a whole) | Regulation, evaluation and introduction (general) 2-channel system Giving OC medicines from the hospital Special permission | |
Introduction for outpatient care | OC evaluation and reimbursement | |
Introduction for hospital care | Assessment of hospital medicines Procurement in hospitals Compassionate use | |
International cooperation | International cooperation HTA Directive HTA Directive concerns | |
Transparency and conflicts of interest management | Transparency | Transparency |
External influences | Lobbying Media role Pharmaceutical industry influence Social pressure | |
Conflicts of interest management | Conflict of interest |